These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Suspected adverse reactions, 2007. Dyer F; Spagnuolo-Weaver M; Coolees S; Tait A Vet Rec; 2008 Jul; 163(3):69-72. PubMed ID: 18702197 [No Abstract] [Full Text] [Related]
43. Reporting of adverse drug reactions by poison control centres in the US. Chyka PA; McCommon SW Drug Saf; 2000 Jul; 23(1):87-93. PubMed ID: 10915034 [TBL] [Abstract][Full Text] [Related]
44. Physicians' liability for adverse drug reactions. Kaufman MB; Stoukides CA; Campbell NA South Med J; 1994 Aug; 87(8):780-4. PubMed ID: 8052883 [TBL] [Abstract][Full Text] [Related]
45. Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis. Psaty BM; Furberg CD; Ray WA; Weiss NS JAMA; 2004 Dec; 292(21):2622-31. PubMed ID: 15572720 [TBL] [Abstract][Full Text] [Related]
46. Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. Qato DM; Alexander GC JAMA; 2011 Oct; 306(14):1595-6. PubMed ID: 21990303 [No Abstract] [Full Text] [Related]
47. Capital punishment and the physician: the views of six Rhode Island physicians. Crowley JP; Ingall MA; Kahr FM; Braden W; Hershkowitz M; Rakatansky H R I Med; 1995 Aug; 78(8):215-21. PubMed ID: 7549022 [No Abstract] [Full Text] [Related]
48. How many deaths occur annually from adverse drug reactions in the United States? Chyka PA Am J Med; 2000 Aug; 109(2):122-30. PubMed ID: 10967153 [TBL] [Abstract][Full Text] [Related]
49. Discovery of new adverse drug reactions. A review of the Food and Drug Administration's spontaneous reporting system. Rossi AC; Knapp DE JAMA; 1984 Aug 24-31; 252(8):1030-3. PubMed ID: 6748207 [TBL] [Abstract][Full Text] [Related]
55. Post-marketing surveillance of drugs. The spontaneous reporting scheme: role of the Adverse Drug Reactions Advisory Committee. Roeser HP; Rohan AP Med J Aust; 1990 Dec 3-17; 153(11-12):720-6. PubMed ID: 2099761 [TBL] [Abstract][Full Text] [Related]
56. Pilot projects to stimulate adverse drug reaction reporting. Fincham JE J Clin Pharm Ther; 1987 Aug; 12(4):243-7. PubMed ID: 3624325 [TBL] [Abstract][Full Text] [Related]
57. Nurses are increasingly involved in pharmacovigilance in Sweden. Ulfvarson J; Mejyr S; Bergman U Pharmacoepidemiol Drug Saf; 2007 May; 16(5):532-7. PubMed ID: 17072915 [TBL] [Abstract][Full Text] [Related]
58. Improving adverse drug reaction reporting in the community setting. McCloskey BA Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690 [TBL] [Abstract][Full Text] [Related]
59. Physician Beliefs About Online Reporting of Quality and Experience Data. Lagu T; Haskell J; Cooper E; Harris DA; Murray A; Gardner RL J Gen Intern Med; 2019 Nov; 34(11):2542-2548. PubMed ID: 31463685 [TBL] [Abstract][Full Text] [Related]
60. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers. Fleuranceau-Morel P Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]